SCHEMBL342302

SCHEMBL342302

CC(C)(C=O)CN1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.38
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.34
ALDH1A1 P00352 3/20 0.34
SIGMAR1 Q99720 1/20 0.33
ATM Q13315 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PSMB1 P20618 2/20 0.33
PSMB5 P28074 2/20 0.33
PSMB2 P49721 2/20 0.33
MAPT P10636 3/20 0.32
HRH3 Q9Y5N1 2/20 0.32
CACNA1B Q00975 1/20 0.32
HPGD P15428 1/20 0.32
GAA P10253 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15541721 1.00 SMN1; SMN2 (0.38) SMN1; SMN2TSHRHSD17B10ALDH1A1SIGMAR1
SCHEMBL341318 0.98 SMN1; SMN2 (0.34) SMN1; SMN2TSHRHSD17B10ALDH1A1SIGMAR1
Piperazine SCHEMBL28078125 0.90 SMN1; SMN2 (0.33) SMN1; SMN2TSHRHSD17B10ALDH1A1
SCHEMBL2420027 0.88
SCHEMBL9957046 0.80 POLB (0.38) SMN1; SMN2ALDH1A1MAPTHRH3POLB
SCHEMBL9957528 0.80 HTT (0.40) ALDH1A1SIGMAR1MAPTHPGD
SCHEMBL12156734 0.79 HRH3 (0.41) SMN1; SMN2TSHRALDH1A1HRH3
SCHEMBL19971101 0.78 SIGMAR1 (0.39) SMN1; SMN2ALDH1A1SIGMAR1MAPTHPGD
SCHEMBL20531089 0.78 GAA (0.35) ALDH1A1GAAPOLB
SCHEMBL342075 0.78 SMN1; SMN2 (0.40) SMN1; SMN2TSHRHSD17B10ALDH1A1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651876-B1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECH AG (CH) 2017-08-09 EP claimed
CN-103313995-B Secondary aminosilanes SIKA技术股份公司 2016-08-10 CN claimed
CN-103261146-B Polyamines having secondary aliphatic amino groups SIKA TECHNOLOGY AG (CH) 2016-01-27 CN claimed
US-8877955-B2 Secondary aminosilanes SIKA TECHNOLOGY AG (CH) 2014-11-04 US claimed
US-20130281562-A1 SECONDARY AMINOSILANES SIKA TECHNOLOGY AG (CH) 2013-10-24 US claimed
EP-2651956-A1 SECONDARY AMINOSILANES Sika Technology AG (CH) 2013-10-23 EP claimed
EP-2651876-A1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS Sika Technology AG (CH) 2013-10-23 EP claimed
US-20130261270-A1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2013-10-03 US claimed
CN-103313995-A Secondary aminosilanes SIKA TECHNOLOGY AG 2013-09-18 CN claimed
CN-103261146-A Polyamines having secondary aliphatic amino groups SIKA TECHNOLOGY AG 2013-08-21 CN claimed
EP-2468759-A1 Secondary Aminosilanes Sika Technology AG (CH) 2012-06-27 EP claimed
WO-2012080266-A1 SECONDARY AMINOSILANES SIKA TECHNOLOGY AG (CH) 2012-06-21 WO claimed
WO-2012080265-A1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2012-06-21 WO claimed
EP-2465843-A1 Polyamines with secondary aliphatic amines Sika Technology AG (CH) 2012-06-20 EP claimed
EP-3484898-B1 METHOD OF STABILIZING IMINO-FUNCTIONAL SILANE MOMENTIVE PERFORMANCE MAT INC (US) 2023-06-28 EP disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
CN-109563111-B Method for stabilizing imino-functional silanes 莫门蒂夫性能材料股份有限公司 2022-04-12 CN disclosed
EP-0236140-A2 Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-09-09 EP disclosed
US-4125530-A FROM 1,1-DIHALO-3,3,3-TRIFLUOROACETONE, BASE, AMMONIA AND A CARBOXALDEHYDE MERCK & CO., INC. (US) 1978-11-14 US disclosed
US-4032522-A ANTI-GOUT, ANTI-HYPERURICEMIC MERCK & CO., INC. (US) 1977-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281562-A1 SECONDARY AMINOSILANES AS3MT, SRM, MSN SMN1; SMN2 542/4885TSHR 4730/4885HSD17B10 4207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.